Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Comprehensive and Advanced Pharmacology

Journal homepage: <https://www.ijcap.in/>

Review Article

Adverse events following immunization (AEFI) for Covid vaccines approved by WHO- A short review

Sutharson Lingadurai^{1,*}, Gurusamy Mariappan²

¹Dept. of Pharmacology, Nirmala College of Health Science, Kunnappilly Post Meloor, Chalakudy, Thrissur, Kerala, India

²Dept. of Pharmaceutical Chemistry, St. Marys College of Pharmacy, Secunderabad, Telangana, India

ARTICLE INFO

Article history:

Received 27-01-2022

Accepted 31-01-2022

Available online 05-03-2022

Keywords:

WHO

SARS-CoV-2

Vaccines

ABSTRACT

The world was suffering and People are in great grief due to COVID 19 Pandemic 2020 and 2021 due to loss of life, jobs and other related socio-economic issues and now it has been in subsiding mode due to the great weapon COVID vaccine. However omicron is now threatening due to high transmissibility compare to other variants of Corona virus. All of us aware corona Vaccines have been permitted by the regulatory authorities of different countries under emergency situation for restricted use. However by considering Risk-Benefit almost >18 age group most of the people have received the vaccine in few countries but yet to reach out all people in the world. The vaccine has reached the market with exemption category and without detailed exploration of all safety parameters. In the current situation it was learned that most of the corona vaccines are safe and Adverse Events Following Immunization (AEFI) associated with all other vaccines are reported except few serious adverse effects. Corona vaccines are in the verge for administration for all age groups. Hence our health care scientist in the globe needs to study and closely to monitor the Safety parameters of all approved vaccines. This short review highlighted the ADRs reported by WHO approved vaccines during clinical trials and in treatment Adverse Events Following Immunization (AEFI).

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](#), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Corona Virus Disease 19 (COVID-19) SARS-CoV-2, 11th March 2020 WHO declared COVID-19 pandemic. In the history of world an infectious disease disaster happened in the late 2019 and still contagious as on date Total no of cases in the world as of 07th Jan 2022- 298,915,721, Total Mortality in the world 5,469,303. But the number of reporting cases and mortality has come down due to many reasons. One of the main reasons is COVID Vaccine. As of 4th Jan 2022, a total of 9,118,223,397 vaccine doses have been administered.¹

1.1. Types of vaccines³

1.1.1. Types of component viral vaccines

1. Protein sub unit: Contains isolated and purified viral proteins
2. Virus Like Particles (VLP): Contains viral proteins that mimic the structure of the virus, but no genetic material
3. DNA/RNA Based: Contains viral genetic material (such as mRNA) which provides instruction for making viral proteins
4. Non-replicating viral vector: Contains viral genetic material packaged inside another harmless virus that cannot copy itself
5. Replicating viral vectors: Contains viral genetic material packaged inside another harmless virus that can copy itself

* Corresponding author.

E-mail address: Sutharson709@gmail.com (S. Lingadurai).

Table 1: ADRs reported in WHO approved vaccines during clinical trial²

Vaccine Name	Manufacturer	Adverse Events
BNT162b2	Pfizer	Common: fever, fatigue, headache, injection site pain Serious: shoulder injury related to vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, myocarditis and right leg paresthesia, fatigue and headache Rare: not reported
mRNA-1273	Moderna	Common: fever, headache, fatigue, myalgia, chills, and injection-site pain Serious: no serious adverse reaction Rare: not reported
AZD1222	Oxford/ AstraZeneca	Common: headache, nausea, myalgia, arthralgia, injection-site tenderness, injection-site pain, injection-site warmth, injection-site pruritus, fatigue, malaise, feverishness, chills Serious: pyrexia, transverse myelitis, hemolytic anemia Rare: not reported
Covaxin	Bharat Biotech	Common: fever, headache, fatigue, nausea, vomiting Serious: not reported Rare: not reported
Covishield	Serum Institute of India	Common: fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea Serious: not reported Rare: not reported
Ad26.COV2.S	Janssen	Common: injection-site pain, headache, myalgia, fatigue, fever Serious: hypotension, bilateral nephrolithiasis in a patient with a history of kidney stones, legionella pneumonia, worsening of multiple sclerosis, fever leading to hospitalization Rare: not reported
CoronaVac	Sinovac	Common: injection-site pain Severe: urticaria Rare: not reported

1.2. Types of whole virus vaccines

1. In activated: Contains copies of the virus that have been killed(Inactivated)
2. Live attenuated: Contains copies of the virus that have been weakened (attenuated)

1.3. WHO approved vaccines for Covid-19

1. **NVX-CoV2373**- Novavax: Vaccine Type - Protein subunit approved by WHO for emergency use in 30 countries.
2. **Covovax (Novavax formulation)**- By Serum Institute of India, Type –Protein Sub Unit, approved in 2 countries
3. **mRNA1273**- Moderna- Type –RNA, approved for 83 countries
4. **BNT162b2**- Pfizer/BioN Tech –Type-RNA, approved in 123 countries
5. **Ad26.COV2.S**- Janssen (Johnson & Johnson) Type - Non replicating viral vector, approved in 95 countries
6. **AZD1222**- Oxford/AstraZeneca Type-Non replicating viral vector approved in 134 countries
7. **Covishield**- Serum Institute of India (Oxford/AstraZeneca formulation), Type-Non replicating viral vector approved in 47 countries
8. **Covaxin**- Bharat Biotech Type-Inactivated, approved in 12 countries
9. **BBIBP-CorV (Vero Cells)**- Sinopharm (Beijing), Type-Inactivated, approved in 80 countries
10. **CoronaVac**- Sinovac, Type-Inactivated, approved in 48 countries

1.4. Adverse events following immunization (AEFI) for Covid vaccines

The common adverse event following immunization (AEFI) with COVID vaccines includes swelling at the site of injection, pain, fever chills are the common one. Fatigue, muscle soreness, headache and joint pain have been reported in most of the receivers.⁴

1.5. Covaxin

A recent study revealed the AEFI reported for Covaxin during 1st dose was 77.27% and with 2nd dose 72.72% respectively. Fever was the most common AEFI experienced in Covaxin.⁴

1.6. Covishield

AEFI reported for Covishield during 1st dose was 92.45% and with 2nd dose 86.79%. Fever was the most common AEFI experienced.⁵ In India through Cowin platform, more than 2300 cases were reported and only 700 Adverse events were reported to be severe (MoHFW, 2021) AEFI Committee has done a deep review of all these reports,

of which only 26 cases were reported to be potential thromboembolic events following the administration of the Covishield vaccine.⁵

In a Pharmacovigilance study for Covishield conducted at Primary Health care workers in Punjab, it was revealed Covishield vaccination in subjects is associated with only minor AEs, and mostly they are manageable with simple measures.

The AEFI Committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic (formation of a clot in a blood vessel that might also break loose and carried by the blood stream to plug another vessel) events — following the administration of Covishield vaccine — with a reporting rate of 0.61 cases/ million doses. In a descriptive study of all the AEFI reported to NCC, PvPI between 16th January 2021 and 31st March 2021 in a tertiary care hospital in India AEFI were observed after first dose of Covishield compared to second dose.⁶ In a Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario, 21 reports of thrombosis with thrombocytopenia syndrome (TTS) after receipt of AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine, of which 16 are vaccine-induced immune thrombotic thrombocytopenia (VITT).

Adverse events study of Covishield on health care workers of 1912 nos performed in a tertiary care hospital at Tigray, Ethiopia. 72hrs post vaccination report analysis shown no serious adverse events.⁷

1.7. BNT162b2

Norway investigates 23 deaths in frail elderly patients after vaccination of BNT162b2 (Pfizer/BioNTech).⁸ During the pivotal phase 3 clinical trials of mRNA COVID-19 vaccines, several cases of facial paralysis were observed in the vaccine groups (7 of 35 654) compared with 1 case among people who received placebo (1 of 35 611).⁹ Myocarditis and pericarditis after COVID-19 vaccination are rare. CDC and FDA have verified 1,124 reports of myocarditis or pericarditis

1.8. CoronaVac

In a study in medical clerkship students in Indonesia for Corona Vac the most common AEFI of SARS-CoV-2 vaccinations was localized pain in the injection site during the first dose with 25 (45%) reports and the booster dose with 34 (67%) reports. Then followed by malaise, the first dose with 20 (36%) reports and the booster dose with 21 (41%) reports. Other symptoms like headache, fever, shivering, sleepiness, nausea, dysphagia, and cold were also reported.¹⁰

1.9. Ad26.COV2. S

Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson's Janssen (J&J/Janssen) COVID-19 vaccination is rare. CDC and FDA identified 57 confirmed reports of people who got the J&J/Janssen COVID-19 vaccine and later developed TTS. CDC has also identified nine deaths that have been caused by or were directly attributed to TTS following J&J/Janssen COVID-19 vaccination. Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 vaccine is rare. After more than 17.2 million J&J/Janssen COVID-19 vaccine doses administered, there have been around 283 preliminary reports of GBS identified. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST (cerebral venous sinus thrombosis) with thrombocytopenia had been identified among the recipients.¹¹

1.10. mRNA-1273

Three confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to Vaccine Adverse Events Reporting System (VAERS) VAERS after more than 470 million doses.⁸ Myocarditis and pericarditis have been reported rarely.

2. Conclusion

The current review has indicated Adverse Events Following Immunization (AEFI) of WHO approved Vaccines. The review put forward the evidences of published research articles in different journals and platforms. It was quite interesting that most of the COVID vaccines have not reported with serious adverse events in the selected population. But it was rarest and rare reported Thromboembolic events with Covishield, Myocarditis and pericarditis with BNT162b2, Thrombosis with thrombocytopenia syndrome (TTS) after Ad26.COV2. S and mRNA-1273. Hence on Risk/Benefit analysis Covid vaccines are Lifesaving medicine for millions of people during this pandemic. However a detailed study of AEFI required for extensive use of these vaccines.

3. Source of Funding

None.

4. Conflict of Interest

The author declares that there is no Conflict of interest.

References

2022. Available from: <https://covid19.who.int/Accessedon7th>.
- Shrestha S, Khatri J, Shakya S, Danekhu K, Khatiwada AP, Sah R, et al. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. *Drugs & Therapy Perspectives*. 2021;37(8):376–82. doi:10.1007/s40267-021-00852-z.
2022. Available from: <https://covid19.trackvaccines.org/types-of-vaccines/>.
- Rajpurohit P, Suva M, Rajpurohit H, Singh Y, Boda P. Retrospective observational survey of adverse events following immunization comparing tolerability of covishield and covaxin vaccines in the real world. *J Pharma and Drug Res*. 2021;2(3):20–25. doi:<https://doi.org/10.53411/jpdr.2021.2.3.5>.
- Kumar R, Singh J, Singh N, Bhandari V. A Study of COVID-19 Vaccine (COVISHIELD) Pharmacovigilance in Primary Healthcare Workers in Punjab, India. *AMEI's Current Trends in Diagn & Treat*. 2021;5(1). doi:10.5005/jp-journals-10055-0111.
- Konda VCR, Gokul T, Poojitha M, Rao KU. Adverse Events Following Immunization to Covid-19 Vaccines in A Tertiary Care Hospital - A Descriptive Study. *Biomed and Pharmacol J*. 2021;14(4):2149–56. doi:<https://dx.doi.org/10.13005/bpj/2312>.
- Tequare MH. Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. *IJID Region*. 2021;1:124–29. doi:<https://doi.org/10.1016/j.ijregi.2021.10.013>.
- Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. *BMJ*. 2021;p. 372–372. doi:<https://doi.org/10.1136/bmj.n149>.
- C S, J H, L Y. Association of Facial Paralysis with mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. *N Engl J Med*. 2021;384(1):20–30. doi:10.1056/NEJMoa2030340.
- Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI, et al. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia. *BMC Pharmacol Toxicol*. 2021;22(1):58. doi:10.1186/s40360-021-00528-4.
- See I, Su JR, Lale A. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. *JAMA*. 2021;325(24):2448–56. doi:10.1001/jama.2021.7517.

Author biography

Sutharson Lingadurai, Professor

Gurusamy Mariappan, Professor

Cite this article: Lingadurai S, Mariappan G. Adverse events following immunization (AEFI) for Covid vaccines approved by WHO- A short review. *IP Int J Comprehensive Adv Pharmacol* 2022;7(1):40-43.